
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-manuscript.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7 H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F392050000468BFA7243FA.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="nihpa" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC2910361/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910361/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Bioorganic &#x00026; medicinal chemistry" /><meta name="citation_title" content="Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7 H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents" /><meta name="citation_author" content="Aleem Gangjee" /><meta name="citation_author_institution" content="Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, United States" /><meta name="citation_author" content="Ying Zhao" /><meta name="citation_author_institution" content="Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, United States" /><meta name="citation_author" content="Sudhir Raghavan" /><meta name="citation_author_institution" content="Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, United States" /><meta name="citation_author" content="Michael A. Ihnat" /><meta name="citation_author_institution" content="Department of Cell Biology, School of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States" /><meta name="citation_author" content="Bryan C. Disch" /><meta name="citation_author_institution" content="Department of Cell Biology, School of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States" /><meta name="citation_publication_date" content="2010/07/07" /><meta name="citation_issue" content="14" /><meta name="citation_volume" content="18" /><meta name="citation_firstpage" content="5261" /><meta name="citation_doi" content="10.1016/j.bmc.2010.05.049" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2910361/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC2910361/" /><meta name="citation_pmid" content="20558072" /><meta name="DC.Title" content="Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7 H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="NIH Public Access" /><meta name="DC.Contributor" content="Aleem Gangjee" /><meta name="DC.Contributor" content="Ying Zhao" /><meta name="DC.Contributor" content="Sudhir Raghavan" /><meta name="DC.Contributor" content="Michael A. Ihnat" /><meta name="DC.Contributor" content="Bryan C. Disch" /><meta name="DC.Date" content="2010 Jul 15" /><meta name="DC.Identifier" content="10.1016/j.bmc.2010.05.049" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7 H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents" /><meta property="og:type" content="article" /><meta property="og:description" content="A series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines analogues 4&#x02013;12 were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate &#x003b1;-bromomethylbenzylketones ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910361/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2910361/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC2910361
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC2910361/pdf/nihms210323.pdf" class="int-view">PDF (2.4M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/2910361/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/2910361/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="2910361" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2910361%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="ysQsduAtA4otgH41iGQzQf1x66b2wyKRA0aB09lTiyZ2dfOs1laG6qTNdWmxv7FS">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2910361%2F&amp;text=Design%2C%20synthesis%20and%20evaluation%20of%202-amino-4-m-bromoanilino-6-arylmethyl-7%20H-pyrrolo%5B2%2C3-d%5Dpyrimidines%20as%20tyrosine%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2910361%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910361/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC2910361/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/20558072/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC2910361/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/20558072/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC2910361/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/2910361/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC2910361
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-nihpa.png" alt="Logo of nihpa" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="https://www.hhs.gov/open/public-access-guiding-principles/index.html" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div><span id="pmcmata">Bioorg Med Chem.</span> Author manuscript; available in PMC 2011 Jul 15.</div><div></div><div class="final-form"><em>Published in final edited form as:</em></div><div class="final-citation"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=20558072" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Bioorg Med Chem. 2010 Jul 15; 18(14): 5261–5273. </a></div><span class="fm-vol-iss-date">Published online 2010 May 25. </span> <span class="doi"><span>doi: </span><a href="//doi.org/10.1016%2Fj.bmc.2010.05.049" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1016/j.bmc.2010.05.049</a></span></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2910361</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS210323</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/20558072">20558072</a></div></div></div><h1 class="content-title">Design, synthesis and evaluation of 2-amino-4-<em>m</em>-bromoanilino-6-arylmethyl-7 <em>H</em>-pyrrolo[2,3-<em>d</em>]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents<sup><a href="#R1" rid="R1" class=" bibr popnode">1</a></sup></h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gangjee%20A%5BAuthor%5D" class="affpopup" co-rid="_co_idm140289027480528" co-class="co-affbox">Aleem Gangjee</a>,<sup>a,</sup><sup>*</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhao%20Y%5BAuthor%5D" class="affpopup" co-rid="_co_idm140289070997824" co-class="co-affbox">Ying Zhao</a>,<sup>a</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Raghavan%20S%5BAuthor%5D" class="affpopup" co-rid="_co_idm140289029189920" co-class="co-affbox">Sudhir Raghavan</a>,<sup>a</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ihnat%20MA%5BAuthor%5D" class="affpopup" co-rid="_co_idm140289032163728" co-class="co-affbox">Michael A. Ihnat</a>,<sup>b</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Disch%20BC%5BAuthor%5D" class="affpopup" co-rid="_co_idm140289032322832" co-class="co-affbox">Bryan C. Disch</a><sup>b</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140289027480528"><h3 class="no_margin">Aleem Gangjee</h3><p><sup>a</sup> Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, United States</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gangjee%20A%5BAuthor%5D">Aleem Gangjee</a></div></div><div id="_co_idm140289070997824"><h3 class="no_margin">Ying Zhao</h3><p><sup>a</sup> Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, United States</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhao%20Y%5BAuthor%5D">Ying Zhao</a></div></div><div id="_co_idm140289029189920"><h3 class="no_margin">Sudhir Raghavan</h3><p><sup>a</sup> Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, United States</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Raghavan%20S%5BAuthor%5D">Sudhir Raghavan</a></div></div><div id="_co_idm140289032163728"><h3 class="no_margin">Michael A. Ihnat</h3><p><sup>b</sup> Department of Cell Biology, School of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ihnat%20MA%5BAuthor%5D">Michael A. Ihnat</a></div></div><div id="_co_idm140289032322832"><h3 class="no_margin">Bryan C. Disch</h3><p><sup>b</sup> Department of Cell Biology, School of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Disch%20BC%5BAuthor%5D">Bryan C. Disch</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140289027842240_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140289027842240_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140289027842240_ai" style="display:none"><div class="fm-affl" id="A1"><sup>a</sup> Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, United States</div><div class="fm-affl" id="A2"><sup>b</sup> Department of Cell Biology, School of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States</div><div id="FN1"><sup>*</sup>
Corresponding author. Tel.: +1 412 396 6070; fax: +1 412 396 5593. <a href="mailto:dev@null" data-email="ude.qud@eejgnag" class="oemail">ude.qud@eejgnag</a> (A. Gangjee)</div></div><div class="fm-article-notes half_rhythm"></div><div class="permissions half_rhythm hide" id="idm140289027842240_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">PMC Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm" role="complementary" aria-label="Related or updated information about this article."><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=20558072" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Bioorg Med Chem</a></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>01.</strong></div><div><a href="/pmc/articles/PMC2910361/bin/NIHMS210323-supplement-01.doc" data-ga-action="click_feat_suppl">NIHMS210323-supplement-01.doc</a><span style="color:gray"> (66K)</span></div><div class="small guid">GUID: F3D7D3A1-ED48-48B8-BA08-E20278D47994</div></div></dd></dl></div><div id="abstract-a.u.b.r" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.u.b.rtitle">Abstract</h2><!--article-meta--><div><p id="P1" class="p p-first-last">A series of 2-amino-4-<em>m</em>-bromoanilino-6-benzyl pyrrolo[2,3-<em>d</em>]pyrimidines analogues <strong>4</strong>&#x02013;<strong>12</strong> were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate &#x003b1;-bromomethylbenzylketones via cyclocondensation with 2,6-diamino-4-pyrimidone to afford the 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-<em>d</em>]pyrimidines. Chlorination at the 4-position followed by displacement with 3-bromoaniline or 3-bromo-<em>N</em>-methylaniline and methylation of the 7-NH afforded the target compounds. Remarkably, dimethylation of both the 4-N and N7 afford whole cell EGFR inhibitors that are more cytotoxic than clinically used erlotinib and mono-methylation at the 4-N or N7 affords more cytotoxic whole cell PDGFR-&#x003b2; inhibitors than clinically used sunitinib. Methylation at either the 4-N or N7 position was detrimental to whole cell VEGFR-2 inhibition. The inhibitory data against the RTKs in this study demonstrates that methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of RTK inhibition.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Multiple receptor, Tyrosine kinase inhibitors, Antiangiogenic agents</span></div></div><div id="S1" class="tsec sec"><h2 class="head no_bottom_margin" id="S1title">1. Introduction</h2><p id="P2" class="p p-first">Angiogenesis is the formation of new blood vessels from pre-existing vasculature. Based on Folkman&#x02019;s seminal observation, in order to grow beyond a few millimeters in diameter, solid tumors depend on the newly formed vasculature network around the tumor mass to provide nutrients and to remove metabolic waste.<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a></sup> It is now well established that angiogenesis plays a key role in the growth of solid tumors, tumor invasion and metastasis.<sup><a href="#R3" rid="R3" class=" bibr popnode">3</a></sup><sup>&#x02013;</sup><sup><a href="#R5" rid="R5" class=" bibr popnode">5</a></sup> The most pronounced factor that triggers angiogenesis is the activation of receptor tyrosine kinases (RTKs) which regulate the transduction of signals from the extracellular domain of endothelial cells to the nucleus.<sup><a href="#R6" rid="R6" class=" bibr popnode">6</a></sup> Abrogation of angiogenesis via RTK inhibition provides an approach for the treatment of cancer. Dysfunctional, hyperactive growth factor RTKs including platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), insulin-like growth factor receptor (IGFR) and epidermal growth factor receptor (EGFR) among others have been associated with several tumors and play a role in tumor angiogenesis.<sup><a href="#R7" rid="R7" class=" bibr popnode">7</a></sup></p><p id="P3">Previously the majority of development of RTK inhibitors was focused on targeting single RTKs. Examples of such clinically used agents include gefitinib (Iressa, specific EGFR inhibitor; approved for use in the treatment of non-small lung cancer) and erlotinib (Tarceva, specific EGFR inhibitor; approved for the treatment of non-small lung cancer) (<a href="/pmc/articles/PMC2910361/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a>).<sup><a href="#R8" rid="R8" class=" bibr popnode">8</a></sup><sup>&#x02013;</sup><sup><a href="#R10" rid="R10" class=" bibr popnode">10</a></sup> Single RTK targeting is specific and does not allow for off target inhibition of other RTK and hence pose little toxicity issues. However, the tumors often survive through an alternative signaling pathway to afford angiogenesis and thus develop resistance to these specific RTK inhibitors. The current paradigm for RTK inhibitors in cancer chemotherapy is the inhibition of multiple, rather than single, RTKs. Recently, additional preclinical studies show that simultaneous inhibition of multiple kinases by single-agents has the potential to increase antitumor activities. The FDA has approved sunitinib and sorafenib (<a href="/pmc/articles/PMC2910361/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a>) as multi targeted agents which show clinical benefit as antitumor agents with minor side effects.<sup><a href="#R11" rid="R11" class=" bibr popnode">11</a></sup><sup>,</sup><sup><a href="#R12" rid="R12" class=" bibr popnode">12</a></sup></p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC2910361/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289032575376"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2910361_nihms210323f1.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2910361/bin/nihms210323f1.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140289032575376"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p>Structures of RTK inhibitors.</p></div></div></div><p id="P4">Using the information provided by the crystal structure of cyclic-AMP-dependent protein kinase, a general pharmacophore model of ATP and the ATP binding site of RTKs has been proposed<sup><a href="#R13" rid="R13" class=" bibr popnode">13</a></sup> and refined.<sup><a href="#R14" rid="R14" class=" bibr popnode">14</a></sup> We have used a general pharmacophore in the anticipation that such a general pharmacophore will afford multi-kinase inhibitory agents. The model proposed (<a href="/pmc/articles/PMC2910361/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a>) consists of an Adenine region which is a hydrophobic binding site for the adenine ring of ATP as well as for the heterocyclic scaffold of inhibitors such as quinazolines and pyrimidines. The N1- and N6-amino nitrogen of the adenine ring of ATP are hydrogen bonded to two amino acid residues of the Hinge region. The Sugar binding pocket in the ATP binding site accommodates the sugar moiety of ATP and the Phosphate binding region binds the triphosphate moiety of ATP. In addition, a Hydrophobic site I extends in the direction of the lone pair of the N7 of ATP and a Hydrophobic site II lies below the Adenine region. Neither hydrophobic site is used by ATP for binding.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC2910361/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289032572912"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f2.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f2.jpg" src="/pmc/articles/PMC2910361/bin/nihms210323f2.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140289032572912"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p>The general ATP-binding site of RTKs. Pharmacophore model of the ATP-binding site of protein kinases. ATP is in pink.</p></div></div></div><p id="P5">On the basis of the general pharmacophore model, Gangjee et al.<sup><a href="#R15" rid="R15" class=" bibr popnode">15</a></sup> embarked on the design of RTK inhibitors using the pyrrolo[ 2,3-<em>d</em>]pyrimidine scaffold with an additional 2-NH<sub>2</sub> moiety which is not present in most other 6&#x02013;6 or 6&#x02013;5 ring system RTK inhibitors. The 2-NH<sub>2</sub> group in our compounds provides a third H-bonding moiety in the Hinge region of RTKs, and was anticipated to increase binding and consequently potency against RTKs. This has recently been shown to be true in most instances, but is dependent on the nature of the scaffold and its substitutions.<sup><a href="#R16" rid="R16" class=" bibr popnode">16</a></sup><sup>,</sup><sup><a href="#R17" rid="R17" class=" bibr popnode">17</a></sup></p><p id="P6">An initial series of 2-amino-4-<em>m</em>-bromoanilino-6-arylmethyl-pyrrolo[ 2,3-<em>d</em>]pyrimidines of structures shown in <a href="/pmc/articles/PMC2910361/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3</span></a> indicated that substitution on the 6-aryl moiety dictates both the selectivity and potency against a variety of RTKs. The most potent compounds of this series were <strong>1</strong>&#x02013;<strong>3</strong> (<a href="/pmc/articles/PMC2910361/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3</span></a>).<sup><a href="#R15" rid="R15" class=" bibr popnode">15</a></sup></p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC2910361/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289025796976"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f3.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f3.jpg" src="/pmc/articles/PMC2910361/bin/nihms210323f3.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140289025796976"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><p>RTK inhibitors.<sup><a href="#R15" rid="R15" class=" bibr popnode">15</a></sup></p></div></div></div><p id="P7">Compounds <strong>1</strong>&#x02013;<strong>3</strong> were docked into the active site of the X-ray crystal structure of EGFR bound to erlotinib (PDB: 1M17<sup><a href="#R18" rid="R18" class=" bibr popnode">18</a></sup>) using Flexx 3.1.2.<sup><a href="#R19" rid="R19" class=" bibr popnode">19</a></sup> Clustering and analysis of the docked poses of the compounds indicated multiple low energy binding modes for the compounds consistent with the literature reports for docked and X-ray crystal structures of small molecules in kinases.<sup><a href="#R20" rid="R20" class=" bibr popnode">20</a></sup> Of the different possible binding modes, three low energy, high scoring important binding modes for <strong>1</strong>&#x02013;<strong>3</strong> are shown in <a href="/pmc/articles/PMC2910361/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4</span></a>. In Mode I, the 2-NH<sub>2</sub> group, N3-nitrogen and 4-NH can hydrogen bond with the Hinge region; the 4-anilino group interacts with Hydrophobic site I and the 6-substituted benzyl ring interacts with the Sugar binding pocket. In binding Mode II hydrogen bonds with the Hinge region can be formed by the 2-NH<sub>2</sub> group, N3-nitrogen and 4-NH: the 4-anilino group interacts with hydrophobic site II and the 6-substituted benzyl ring interacts with the Sugar binding pocket. Binding Mode III is obtained from Mode I by rotating 180&#x000b0; around the C&#x02013;N bond between C-2 and the 2-NH<sub>2</sub>. In Mode III, the N7-pyrrolo nitrogen replaces the 4-NH and hydrogen bonds with the Hinge region. The anilino group interacts with the Sugar binding pocket and the 6-substituted benzyl ring interacts with the Hydrophobic site I (<a href="/pmc/articles/PMC2910361/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4</span></a>). These binding modes were among those observed within 2 kcal/mol of the lowest energy poses obtained during multiple docking iterations of <strong>1</strong>&#x02013;<strong>3</strong> using Flexx 3.1.2.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F4" co-legend-rid="lgnd_F4"><a href="/pmc/articles/PMC2910361/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289025794256"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2910361_nihms210323f4.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f4.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2910361/bin/nihms210323f4.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140289025794256"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Figure 4</a></div><!--caption a7--><div class="caption"><p>Proposed binding modes of pyrrolo[2,3-<em>d</em>]pyrimidines to RTKs.</p></div></div></div><p id="P8" class="p p-last">We reasoned that hypothetical modes of binding illustrated in <a href="/pmc/articles/PMC2910361/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4</span></a> could be substantiated by introduction of strategically placed methyl substitutions at the N7- and/or 4-N positions and evaluation of the resulting analogues for RTK activity. These methyl substitutions would preclude the N7- and/or 4-N from functioning as a hydrogen bond donor as required by all three proposed modes of binding (<a href="/pmc/articles/PMC2910361/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4</span></a>). Thus, starting with the three most potent compounds (<strong>1&#x02013;3</strong>) previously synthesized, each analogue was substituted in the 4-N position (compounds <strong>4, 7</strong>, and <strong>10</strong>), the N7-position (<strong>5, 8</strong>, and <strong>11</strong>) and both the 4-N and N7-positions (<strong>6, 9</strong>, and <strong>12</strong>) with methyl group(s) (<a href="/pmc/articles/PMC2910361/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5</span></a>). Thus, if Mode I and/or Mode II was/were the only binding mode(s) and the 4-NH was necessary for binding, compounds <strong>4</strong>, <strong>6</strong>, <strong>7</strong>, <strong>9</strong>, <strong>10</strong>, and <strong>12</strong> should be poorly active; on the other hand, if Mode III was the only binding mode and the N7-H was necessary for binding, compounds <strong>5</strong>, <strong>6</strong>, <strong>8</strong>, <strong>9</strong>, <strong>11</strong>, and <strong>12</strong> should be poorly active. If however, all three modes were possible, only compounds <strong>6, 9</strong>, and <strong>12</strong> should be poorly active since they lack H-bonding donor ability at both the 4-N and N7. In addition, methylation at the N7- and/or the 4-N also influences the conformation of the 6-substituent and/or the 4-substituent (respectively) with respect to the pyrrolo[2,3-<em>d</em>]pyrimidine scaffold and could also, in part, influence the potency and selectivity of the methylated compounds compared with the unmethylated analogs.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F5" co-legend-rid="lgnd_F5"><a href="/pmc/articles/PMC2910361/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289067867824"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2910361_nihms210323f5.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f5.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2910361/bin/nihms210323f5.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140289067867824"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F5"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5">Figure 5</a></div></div></div></div><div id="S2" class="tsec sec"><h2 class="head no_bottom_margin" id="S2title">2. Chemistry</h2><p id="P9" class="p p-first-last">The synthetic method for target compounds <strong>4</strong>&#x02013;<strong>12</strong> is shown in <a href="/pmc/articles/PMC2910361/figure/F15/" target="figure" class="fig-table-link figpopup" rid-figpopup="F15" rid-ob="ob-F15" co-legend-rid="lgnd_F15"><span>Scheme 1</span></a>. The key intermediates in the synthesis are 2-pivaloylamino-4-chloro-6-(substitutedbenzyl)-pyrrolo[2,3-<em>d</em>]pyrimidine, <strong>17a</strong>&#x02013;<strong>c</strong>, which were converted to the target compounds via nucleophilic substitution with appropriate anilines or methylation with MeI followed by nucleophilic substitution with appropriate anilines. Compounds <strong>17a</strong>&#x02013;<strong>c</strong> were synthesized from commercially available acids <strong>13a&#x02013;c</strong>, respectively, via treatment with thionyl chloride followed by diazomethane (generated from <em>N</em>-nitroso-<em>N-</em>methyl urea) in an ice-bath to afford the &#x003b1;-diazoketones, which were converted to the &#x003b1;-bromoketones <strong>14a&#x02013;c</strong> with 48% HBr solution. Cyclocondensation of <strong>14a&#x02013;c</strong> with 2,6-diamino-4-hydroxypyrimidine at room temperature in DMF for 3 days afforded regiospecifically the 2-amino-4-oxo-6-benzylpyrrolo[2,3-<em>d</em>]pyrimidines <strong>15a&#x02013;c</strong> in 20&#x02013;37% yield. Protecting the 2-amino group of <strong>15a&#x02013;c</strong> with pivalic anhydride afforded <strong>16a</strong>&#x02013;<strong>c</strong> in 20&#x02013;37% yield, which were further converted to <strong>17a</strong>&#x02013;<strong>c</strong> in 31&#x02013;78% yield via chlorination with POCl<sub>3</sub>. With the key intermediates <strong>17a</strong>&#x02013;<strong>c</strong> in hand, the target compounds <strong>4, 7</strong>, and <strong>10</strong> were obtained by nucleophilic displacement of the 4-chloro moiety of <strong>17a&#x02013;c</strong> with 3-bromo-<em>N-</em>methyl aniline in isopropyl alcohol at reflux for 4 h in the presence of 2&#x02013;3 drops of concd HCl and then deprotected with 15% potassium hydroxide in 14&#x02013;20% yield. Methylation of <strong>17a&#x02013;c</strong> with MeI at 0&#x02013;5 &#x000b0;C in THF gave <strong>18a&#x02013;c</strong> in 57&#x02013;77% yield, which afforded the target compounds <strong>5, 8</strong>, and <strong>11</strong> in 42&#x02013;58% yield via nucleophilic substitution with 3-bromoaniline followed by deprotection of the 2-pivaloyl group. The target compounds <strong>6, 9</strong>, and <strong>12</strong> were obtained in 27&#x02013;33% yield by displacement of the 4-chloro moiety of <strong>18a&#x02013;c</strong> with 3-bromo-<em>N</em>-methyl aniline and deprotection of the 2-pivaloyl group.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F15" co-legend-rid="lgnd_F15"><a href="/pmc/articles/PMC2910361/figure/F15/" target="figure" rid-figpopup="F15" rid-ob="ob-F15"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289027798416"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2910361_nihms210323f15.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f15.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2910361/bin/nihms210323f15.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140289027798416"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F15/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F15"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F15/" target="figure" rid-figpopup="F15" rid-ob="ob-F15">Scheme 1</a></div><!--caption a7--><div class="caption"><p>Synthesis of <strong>4</strong>&#x02013;<strong>12</strong>. Reagents and conditions: (a) (1) SOCl<sub>2</sub>, benzene, reflux, 1 h; (2) CH<sub>2</sub>N<sub>2</sub>/Et<sub>2</sub>O, 30 m; (3) 47.5% HBr, 70&#x02013;80 &#x000b0;C, 1 h; (b) 2,6-diamino-4-hydroxypyrimidine, DMF, rt, 3 days; (c) Piv<sub>2</sub>O, reflux, 3 h; (d) POCl<sub>3</sub>, reflux, 3 h; (e) MeI, NaH, THF, 0&#x02013;25 &#x000b0;C; (f) (1) <em>i</em>-PrOH, 3-bromo-<em>N</em>-methyl aniline, 2&#x02013;3 drops of concd HCl, reflux, 30 m; (2) 15% KOH, 1,4-dioxane, reflux, 10 h; (g) (1) <em>i</em>-PrOH, 3-bromoaniline 2&#x02013;3 drops of concd HCl, reflux, 30 m; (2) 15% KOH, 1,4-dioxane, reflux, 10 h; (h) (1) <em>i</em>-PrOH, 3-bromo-<em>N</em>-methyl aniline, 2&#x02013;3 drops of concd HCl, reflux, 30 m; (2) 15% KOH, 1,4-dioxane, reflux, 10 h.</p></div></div></div></div><div id="S3" class="tsec sec"><h2 class="head no_bottom_margin" id="S3title">3. Results and discussion</h2><p id="P10" class="p p-first">The RTK inhibitory activity of the compounds were determined using human tumor cells known to express high levels of EGFR, VEGFR-2, and PDGFR-&#x003b2;, respectively, as we have reported previously and are listed in <a href="/pmc/articles/PMC2910361/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>.<sup><a href="#R15" rid="R15" class=" bibr popnode">15</a></sup> Cytotoxicity studies against the growth of A431 cells, which over-express EGFR, in culture, were also carried out for these compounds and are listed in <a href="/pmc/articles/PMC2910361/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. In all cases, assays were carried out 2&#x02013;3 times with 4&#x02013;5 replicates per assay. In addition, the effect of <strong>4</strong>&#x02013;<strong>12</strong> on new blood vessel formation (angiogenesis) was assessed using the chicken embryo chorioallantonic membrane (CAM) assay, a standard test for angiogenesis and are listed in <a href="/pmc/articles/PMC2910361/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. Since the IC<sub>50</sub> values of compounds vary under different assay conditions (e.g., ATP concentrations etc.) we used standard (control) compounds in each of the evaluations. Clinically used erlotinib and <em>N</em>-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine <strong>19</strong> (PD153035, <a href="/pmc/articles/PMC2910361/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a>)<sup><a href="#R21" rid="R21" class=" bibr popnode">21</a></sup> were used as standards for EGFR inhibition. Clinically used sunitinib and (<em>Z</em>)-3-[4-(dimethylamino)benzylidenyl]indolin-2-one, <strong>20</strong> (SU4312, <a href="/pmc/articles/PMC2910361/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a>)<sup><a href="#R22" rid="R22" class=" bibr popnode">22</a></sup> were used as standards for PDGFR-&#x003b2; inhibition. Sunitinib and semaxanib (<a href="/pmc/articles/PMC2910361/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a>) were used as standards for VEGFR-2 inhibition and semaxanib was used as a standard for the CAM assay and cisplatin was used as a standard for the A431 cytotoxicity assay.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p>IC<sub>50</sub> values (&#x003bc;M) of kinase inhibition, A431 cytotoxicity, and inhibition of the CAM assay</p></div><div class="xtable"><table frame="below" rules="groups" class="rendered small default_table"><thead><tr><th colspan="6" valign="bottom" align="left" rowspan="1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289021624496"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323u1.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323u1.jpg" src="/pmc/articles/PMC2910361/bin/nihms210323u1.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140289021624496"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/table/T1/?report=objectonly">Open in a separate window</a></div><hr /></th></tr><tr><th valign="bottom" align="left" rowspan="1" colspan="1">Compound</th><th valign="bottom" align="left" rowspan="1" colspan="1">EGFR inhibition</th><th valign="bottom" align="left" rowspan="1" colspan="1">VEGFR-2 inhibition</th><th valign="bottom" align="left" rowspan="1" colspan="1">PDGFR-&#x003b2; inhibition</th><th valign="bottom" align="left" rowspan="1" colspan="1">A431 Cytotoxicity</th><th valign="bottom" align="left" rowspan="1" colspan="1">CAM angiogenesis inhibition</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>1</strong></td><td align="left" valign="top" rowspan="1" colspan="1">1.67</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;50</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;50</td><td align="left" valign="top" rowspan="1" colspan="1">31.8</td><td align="left" valign="top" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>2</strong></td><td align="left" valign="top" rowspan="1" colspan="1">9.19</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;50</td><td align="left" valign="top" rowspan="1" colspan="1">1.21</td><td align="left" valign="top" rowspan="1" colspan="1">1.21</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>3</strong></td><td align="left" valign="top" rowspan="1" colspan="1">12.62</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td><td align="left" valign="top" rowspan="1" colspan="1">8.92</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;50</td><td align="left" valign="top" rowspan="1" colspan="1">1.32</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>4</strong></td><td align="left" valign="top" rowspan="1" colspan="1">53.1</td><td align="left" valign="top" rowspan="1" colspan="1">89.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;500</td><td align="left" valign="top" rowspan="1" colspan="1">45.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.56</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>5</strong></td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;200</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;200</td><td align="left" valign="top" rowspan="1" colspan="1">2.8</td><td align="left" valign="top" rowspan="1" colspan="1">27.9</td><td align="left" valign="top" rowspan="1" colspan="1">6.22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>6</strong></td><td align="left" valign="top" rowspan="1" colspan="1">253.6</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;200</td><td align="left" valign="top" rowspan="1" colspan="1">71.7</td><td align="left" valign="top" rowspan="1" colspan="1">50.9</td><td align="left" valign="top" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>7</strong></td><td align="left" valign="top" rowspan="1" colspan="1">31.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;200</td><td align="left" valign="top" rowspan="1" colspan="1">34.8</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;500</td><td align="left" valign="top" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>8</strong></td><td align="left" valign="top" rowspan="1" colspan="1">12.8</td><td align="left" valign="top" rowspan="1" colspan="1">116.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;500</td><td align="left" valign="top" rowspan="1" colspan="1">204.3</td><td align="left" valign="top" rowspan="1" colspan="1">3.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>9</strong></td><td align="left" valign="top" rowspan="1" colspan="1">1.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;200</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;500</td><td align="left" valign="top" rowspan="1" colspan="1">226.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>10</strong></td><td align="left" valign="top" rowspan="1" colspan="1">143.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;200</td><td align="left" valign="top" rowspan="1" colspan="1">1.3</td><td align="left" valign="top" rowspan="1" colspan="1">197.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>11</strong></td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;200</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;200</td><td align="left" valign="top" rowspan="1" colspan="1">348.0</td><td align="left" valign="top" rowspan="1" colspan="1">35.6</td><td align="left" valign="top" rowspan="1" colspan="1">3.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>12</strong></td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;200</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;500</td><td align="left" valign="top" rowspan="1" colspan="1">94.1</td><td align="left" valign="top" rowspan="1" colspan="1">2.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>19</strong></td><td align="left" valign="top" rowspan="1" colspan="1">0.23</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>20</strong></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1">3.75</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Semaxanib</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1">12.9</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cisplatin</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1">10.6</td><td align="left" valign="top" rowspan="1" colspan="1">18.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Erlotinib</td><td align="left" valign="top" rowspan="1" colspan="1">1.2</td><td align="left" valign="top" rowspan="1" colspan="1">124.7</td><td align="left" valign="top" rowspan="1" colspan="1">83.1</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1">29.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sunitinib</td><td align="left" valign="top" rowspan="1" colspan="1">172.1</td><td align="left" valign="top" rowspan="1" colspan="1">18.9</td><td align="left" valign="top" rowspan="1" colspan="1">12.2</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1">1.3</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140289027918336"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/table/T1/?report=objectonly">Open in a separate window</a></div></div><p id="P11">In the EGFR whole cell assay (<a href="/pmc/articles/PMC2910361/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>), mono-methylation on either the 4-NH or N7-position resulted in decreased activity or inactive compounds compared with the standard, <strong>19</strong> but more cytotoxic (<strong>12</strong>) or equipotent with erlotinib. The 4-N, N7-dimethylated compounds <strong>9</strong> and <strong>12</strong> were the most potent and were eight-fold and 25-fold more potent than the lead compounds <strong>2</strong> and <strong>3</strong>, respectively. However, the 4-NH, N7-dimethylated compound <strong>6</strong> was much less potent than its lead compound <strong>1</strong> indicating that the substitution on the 6-benzyl ring is also an important determinant for activity. Compounds <strong>1</strong> and <strong>9</strong> were as active as erlotinib, an EGFR inhibitor, while <strong>12</strong> was twice as active against EGFR as compared to erlotinib.</p><p id="P12">In an attempt to explain the activity against EGFR in the whole cell assay, molecular modeling studies were performed for <strong>1</strong>&#x02013;<strong>12</strong> using Flexx 3.1.2 using docking into the X-ray crystal structure of the 4-anilinoquinazoline inhibitor erlotinib in EGFR (PDB ID: 1M17). Multiple low energy binding modes were observed for all the docked compounds. The binding mode presented in <a href="/pmc/articles/PMC2910361/figure/F6/" target="figure" class="fig-table-link figpopup" rid-figpopup="F6" rid-ob="ob-F6" co-legend-rid="lgnd_F6"><span>Figure 6</span></a> for <strong>1</strong>&#x02013;<strong>3</strong> was observed to be within 2 kcal/mol of the lowest energy pose and permitted comparison between the proposed binding modes of the three molecules. All the molecules form hydrogen bonds with the Hinge region using the 2-NH<sub>2</sub> moiety. Additional hydrogen bonding using the N3-nitrogen is observed for <strong>1</strong> and <strong>2</strong> but not <strong>3</strong>. Hinge region hydrogen bonds with the 4-NH is observed for <strong>1</strong> and <strong>3</strong> but not <strong>2</strong>. This explains, in part, the greater potency of <strong>1</strong> against EGFR compared with <strong>2</strong> and <strong>3</strong>. The anilino rings of the three compounds reside in Hydrophobic site II and are flanked by Leu694, Leu768, and Pro770. The 6-benzyl moieties of the molecules extend into the Sugar binding pocket and interact with a hydrophobic pocket formed by Leu694, Phe699, and Val702. The altered conformations of the side chain benzyl ring in <strong>2</strong> due to the 2&#x02032;-CH<sub>3</sub> and in <strong>3</strong> due to the 2&#x02032;-,5&#x02032;-dimethoxy cause the benzyl ring to extend away from Val702, reducing the extent of hydrophobic stabilization of these molecules. Ligand interaction plots for <strong>1</strong>&#x02013;<strong>3</strong> are shown in <a href="/pmc/articles/PMC2910361/figure/F7/" target="figure" class="fig-table-link figpopup" rid-figpopup="F7" rid-ob="ob-F7" co-legend-rid="lgnd_F7"><span>Figure 7(A&#x02013;C)</span></a>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F6" co-legend-rid="lgnd_F6"><a href="/pmc/articles/PMC2910361/figure/F6/" target="figure" rid-figpopup="F6" rid-ob="ob-F6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289022163824"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f6.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f6.jpg" src="/pmc/articles/PMC2910361/bin/nihms210323f6.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140289022163824"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F6"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F6/" target="figure" rid-figpopup="F6" rid-ob="ob-F6">Figure 6</a></div><!--caption a7--><div class="caption"><p>Stereoview. Overlay of docked poses of <strong>1</strong> (red), <strong>2</strong> (white) and <strong>3</strong> (blue) in EGFR active site (PDB code 1M17).</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F7" co-legend-rid="lgnd_F7"><a href="/pmc/articles/PMC2910361/figure/F7/" target="figure" rid-figpopup="F7" rid-ob="ob-F7"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289028734368"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2910361_nihms210323f7.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f7.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2910361/bin/nihms210323f7.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140289028734368"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F7/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F7"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F7/" target="figure" rid-figpopup="F7" rid-ob="ob-F7">Figure 7</a></div><!--caption a7--><div class="caption"><p>Ligand interaction plots of docked poses of <strong>1</strong> (A), <strong>2</strong> (B), and <strong>3</strong> (C) in the EGFR active site.</p></div></div></div><p id="P13">Docked poses of the 4-N methylated compound <strong>4</strong> in EGFR (PDB ID: 1M17) show the loss of hydrogen bonding to the backbone of Met769 afforded by the 4-NH group in the unmethylated lead compound <strong>1</strong> (<a href="/pmc/articles/PMC2910361/figure/F8/" target="figure" class="fig-table-link figpopup" rid-figpopup="F8" rid-ob="ob-F8" co-legend-rid="lgnd_F8"><span>Figs. 8</span></a> and <a href="/pmc/articles/PMC2910361/figure/F9/" target="figure" class="fig-table-link figpopup" rid-figpopup="F9" rid-ob="ob-F9" co-legend-rid="lgnd_F9"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and9).</span></span><span>9</span></a>). Additionally, to accommodate the 4-N methyl group, <strong>4</strong> is oriented farther from the Hinge region as compared to <strong>1</strong>. This results in the loss of a hydrogen bond of the N3-nitrogen with the backbone of Met769. Additional binding interactions afforded by other portions of <strong>4</strong> are analogous to those seen in <strong>1</strong>. This loss in H-bonding of the N3 in <strong>4</strong> could explain, in part, its reduction in whole cell activity against EGFR as compared to <strong>1</strong> which lacks the 4-N methyl group (see <a href="/pmc/articles/PMC2910361/figure/F8/" target="figure" class="fig-table-link figpopup" rid-figpopup="F8" rid-ob="ob-F8" co-legend-rid="lgnd_F8"><span>Figs. 8</span></a> and <a href="/pmc/articles/PMC2910361/figure/F9/" target="figure" class="fig-table-link figpopup" rid-figpopup="F9" rid-ob="ob-F9" co-legend-rid="lgnd_F9"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and9</span></span><span>9</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F8" co-legend-rid="lgnd_F8"><a href="/pmc/articles/PMC2910361/figure/F8/" target="figure" rid-figpopup="F8" rid-ob="ob-F8"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289022743344"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f8.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f8.jpg" src="/pmc/articles/PMC2910361/bin/nihms210323f8.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140289022743344"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F8/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F8"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F8/" target="figure" rid-figpopup="F8" rid-ob="ob-F8">Figure 8</a></div><!--caption a7--><div class="caption"><p>Stereoview. Overlay of docked poses of <strong>1</strong> (red) and <strong>4</strong> (white) in EGFR active site.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F9" co-legend-rid="lgnd_F9"><a href="/pmc/articles/PMC2910361/figure/F9/" target="figure" rid-figpopup="F9" rid-ob="ob-F9"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289069438992"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2910361_nihms210323f9.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f9.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2910361/bin/nihms210323f9.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140289069438992"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F9/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F9"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F9/" target="figure" rid-figpopup="F9" rid-ob="ob-F9">Figure 9</a></div><!--caption a7--><div class="caption"><p>(A) Ligand interaction plots of docked pose of <strong>4</strong> in the EGFR active site. (B) Overlay of ligand interaction plots of docked poses of <strong>4</strong> (red) and <strong>1</strong> (green) in the EGFR active site. MOE 2009.10.</p></div></div></div><p id="P14">When comparing the 4-N, N7-dimethylated compounds <strong>6</strong>, <strong>9</strong>, and <strong>12</strong>, it was noted that the whole cell activity of the compounds increase with increasing size of the substitution on the 6-benzyl ring. This trend is in contrast to that for the lead compounds <strong>1</strong>&#x02013;<strong>3</strong>. Docking studies with <strong>12</strong> (<a href="/pmc/articles/PMC2910361/figure/F10/" target="figure" class="fig-table-link figpopup" rid-figpopup="F10" rid-ob="ob-F10" co-legend-rid="lgnd_F10"><span>Figs. 10</span></a> and <a href="/pmc/articles/PMC2910361/figure/F11/" target="figure" class="fig-table-link figpopup" rid-figpopup="F11" rid-ob="ob-F11" co-legend-rid="lgnd_F11"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and11)</span></span><span>11</span></a>) indicated that this compound adopts a binding mode different from that seen with the docked poses of <strong>1</strong>&#x02013;<strong>3</strong>. In the docked pose of <strong>12</strong> (<a href="/pmc/articles/PMC2910361/figure/F10/" target="figure" class="fig-table-link figpopup" rid-figpopup="F10" rid-ob="ob-F10" co-legend-rid="lgnd_F10"><span>Fig. 10</span></a>), the 2-NH<sub>2</sub> moiety is involved in the lone Hinge region hydrogen bond. The 4-N and N7-methyl groups alter the conformation of the molecule and permits the anilino portion to access Hydrophobic site I. The 2&#x02032;,5&#x02032;-dimethoxybenzyl side chain accesses the Sugar binding pocket and is placed in a hydrophobic site formed by Leu694, Phe699, and Val702. The 2&#x02032;,5&#x02032;-dimethoxy moieties provides additional hydrogen bonds with Thr766 and Lys721. The conformational change due to 4-N, N7-dimethylation and additional interactions due to the nature and orientation of the benzyl side chain could be anticipated to compensate for the loss of hydrogen bonding by either the 4-N or N7 nitrogen atom and contribute to the increased potency of <strong>12</strong> against EGFR in whole cell assays compared with <strong>3</strong>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F10" co-legend-rid="lgnd_F10"><a href="/pmc/articles/PMC2910361/figure/F10/" target="figure" rid-figpopup="F10" rid-ob="ob-F10"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289072589504"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f10.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f10.jpg" src="/pmc/articles/PMC2910361/bin/nihms210323f10.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140289072589504"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F10/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F10"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F10/" target="figure" rid-figpopup="F10" rid-ob="ob-F10">Figure 10</a></div><!--caption a7--><div class="caption"><p>Stereoview. Overlay of docked poses of <strong>12</strong> (red) and <strong>3</strong> (white) in EGFR active site.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F11" co-legend-rid="lgnd_F11"><a href="/pmc/articles/PMC2910361/figure/F11/" target="figure" rid-figpopup="F11" rid-ob="ob-F11"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289030119088"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2910361_nihms210323f11.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f11.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2910361/bin/nihms210323f11.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140289030119088"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F11/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F11"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F11/" target="figure" rid-figpopup="F11" rid-ob="ob-F11">Figure 11</a></div><!--caption a7--><div class="caption"><p>(A) Ligand interaction plots of docked pose of <strong>12</strong> in the EGFR active site. (B) Overlay of ligand interaction plots of docked poses of <strong>12</strong> (red) and <strong>3</strong> (green) in the EGFR active site.</p></div></div></div><p id="P15">All the mono- and di-methylated derivatives were comparatively inactive against VEGFR-2 in whole cell assays. This suggests that for VEGFR-2 inhibition, in whole cells, both the 4-NH and 7-NH protons are important for binding and necessary for activity. Whether this reflects space requirements or hydrogen bond donor ability at the 4-NH- and N7-positions is not clear and is currently under investigation.</p><p id="P16">In the PDGFR-&#x003b2; whole cell assay, compound <strong>10</strong>, the 4-N-methyl analogue, was the most potent and was about ninefold more potent than sunitinib, about threefold more potent than the standard, <strong>20</strong> and sevenfold more potent than its lead analogue <strong>3</strong>. Compound <strong>5</strong>, which has a methyl group on the N7-position showed fourfold greater activity than sunitinib, comparable whole cell PDGFR-&#x003b2; inhibition with the standard, <strong>20</strong> and was over 20-fold more potent than the lead analogue <strong>1</strong>. The 4-N-methylated compound <strong>7</strong> showed increased activity compared with its lead <strong>2</strong>. This suggests that methylation on either the 4-NH or N7 increases the inhibitory activity against whole cell PDGFR-&#x003b2;. However, the N7-methylation of <strong>1</strong> to afford <strong>5</strong> increases the activity against whole cell PDGFR-&#x003b2; almost three-times greater than that for <strong>10</strong> over <strong>3</strong>.</p><p id="P17">There is currently no crystal structure of PDGFR-&#x003b2; bound to a ligand. Using the structure of c-KIT kinase complex (PDB: 1PKG, chain A)<sup><a href="#R23" rid="R23" class=" bibr popnode">23</a></sup> as the template a homology model of PDGFR-&#x003b2; was generated using the Molecular Operating Environment (MOE 2007.09) suite.<sup><a href="#R24" rid="R24" class=" bibr popnode">24</a></sup> Molecular modeling studies were performed using Flexx 3.1.2 as described above in an attempt to explain the increased activity of <strong>10</strong> compared with <strong>3</strong> against whole cell assays for PDGFR-&#x003b2;.</p><p id="P18"><a href="/pmc/articles/PMC2910361/figure/F12/" target="figure" class="fig-table-link figpopup" rid-figpopup="F12" rid-ob="ob-F12" co-legend-rid="lgnd_F12"><span>Figure 12</span></a> shows the best docked pose of <strong>3</strong> within 2 kcal/mol of the lowest energy pose in the active site of the homology model of PDGFR-&#x003b2;. In this pose the pyrrolo[2,3-<em>d</em>]pyrimidine ring of <strong>3</strong> rests in the Adenine binding region and forms hydrogen bonds with Glu682 and Cys684 in the Hinge region via the N-1, 2-NH<sub>2</sub>, and N-7 nitrogen atoms. These interactions serve to anchor the molecule and permit the anilino moiety to access Hydrophobic site I where it can interact with hydrophobic residues Ala848, Val614, and Leu606. The 2&#x02032;-methoxy substituent on the 6-benzyl moiety can form a hydrogen bond with the backbone of Asp688. The docked pose of <strong>10</strong> in the homology model (<a href="/pmc/articles/PMC2910361/figure/F13/" target="figure" class="fig-table-link figpopup" rid-figpopup="F13" rid-ob="ob-F13" co-legend-rid="lgnd_F13"><span>Fig. 13</span></a>) also maintains these interactions seen in the docked pose of <strong>3</strong>. In addition, <strong>10</strong>, which is methylated at the 4-N, binds in a mode which orients the anilino moiety deeper in Hydrophobic Site I. The bromophenyl residues can form hydrophobic interactions with Val614, Leu606, Val665 (not shown), Phe845 and Ala848 and the side chain of Lys634. Additionally, the methyl group on the 4-N can form hydrophobic interactions with Val614 and Ala848 and provide additional stabilization of the pose. Together, these interactions could account, in part, for the improvement in activity of <strong>10</strong> over the lead compound <strong>3</strong>. <a href="/pmc/articles/PMC2910361/figure/F14/" target="figure" class="fig-table-link figpopup" rid-figpopup="F14" rid-ob="ob-F14" co-legend-rid="lgnd_F14"><span>Figure 14</span></a> shows the ligand interaction plots for <strong>3</strong> and <strong>10</strong> in the active site of the PDGFR-&#x003b2; homology model (see <a href="/pmc/articles/PMC2910361/figure/F14/" target="figure" class="fig-table-link figpopup" rid-figpopup="F14" rid-ob="ob-F14" co-legend-rid="lgnd_F14"><span>Fig. 14</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F12" co-legend-rid="lgnd_F12"><a href="/pmc/articles/PMC2910361/figure/F12/" target="figure" rid-figpopup="F12" rid-ob="ob-F12"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289029562528"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f12.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f12.jpg" src="/pmc/articles/PMC2910361/bin/nihms210323f12.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140289029562528"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F12/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F12"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F12/" target="figure" rid-figpopup="F12" rid-ob="ob-F12">Figure 12</a></div><!--caption a7--><div class="caption"><p>Stereoview. Docked pose of <strong>3</strong> (white) in PDGFR-&#x003b2; homology model.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F13" co-legend-rid="lgnd_F13"><a href="/pmc/articles/PMC2910361/figure/F13/" target="figure" rid-figpopup="F13" rid-ob="ob-F13"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289016095088"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f13.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f13.jpg" src="/pmc/articles/PMC2910361/bin/nihms210323f13.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140289016095088"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F13/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F13"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F13/" target="figure" rid-figpopup="F13" rid-ob="ob-F13">Figure 13</a></div><!--caption a7--><div class="caption"><p>Stereoview. Overlay of docked poses of <strong>10</strong> (red) and <strong>3</strong> (white) in PDGFR-&#x003b2; homology model.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F14" co-legend-rid="lgnd_F14"><a href="/pmc/articles/PMC2910361/figure/F14/" target="figure" rid-figpopup="F14" rid-ob="ob-F14"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140289033885216"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2910361_nihms210323f14.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms210323f14.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2910361/bin/nihms210323f14.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140289033885216"><a target="object" rel="noopener" href="/pmc/articles/PMC2910361/figure/F14/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F14"><div><a class="figpopup" href="/pmc/articles/PMC2910361/figure/F14/" target="figure" rid-figpopup="F14" rid-ob="ob-F14">Figure 14</a></div><!--caption a7--><div class="caption"><p>(A) Ligand interaction plots of docked pose of <strong>3</strong> in the PDGFR-&#x003b2; model. (B) Overlay of ligand interaction plots of docked poses of <strong>3</strong> (red) and <strong>10</strong> (green) in the PDGFR-&#x003b2; model.</p></div></div></div><p id="P19">The docked pose of <strong>5</strong> (not shown) was similar to binding Mode II (<a href="/pmc/articles/PMC2910361/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4</span></a>). Hydrogen bonding interactions with the 2-NH<sub>2</sub> and 4-NH moieties were maintained with the Hinge region. The anilino moiety occupied Hydrophobic region II while the 6-benzyl moiety occupied the Sugar binding pocket.</p><p id="P20">Cytotoxicity studies against the growth of A431 (human cancer cells that over-express EGFR) in culture provided interesting results. All of the methylated compounds were less potent than the standard compound, cisplatin. The most potent compound was the N7-methyl substituted compound <strong>5</strong>. This was comparable with its lead <strong>1</strong>. However, compound <strong>2</strong> which was ninefold more potent than the standard, cisplatin against A431 when substituted at the 4-N or N7 or both, afforded compounds (<strong>7</strong>&#x02013;<strong>9</strong>) that were inactive. The same modification for compound <strong>3</strong> also afforded inactive compounds (<strong>10</strong>&#x02013;<strong>11</strong>). This suggests that 4-N- or N7-methylation is not conducive to A431 cytotoxicity. The data for most of the analogues do not correlate EGFR inhibitory activity (or inactivity) with A431 inhibitory activity (or inactivity). The most potent analogues against EGFR, compounds <strong>9</strong> and <strong>12</strong>, were inactive against A431 cells; compounds <strong>5</strong> and <strong>11</strong> which were completely inactive against EGFR showed the most potent inhibitory activity against A431 among all the methylated analogues. These unexpected results for A431 inhibition could reflect transport and/or other factors which influence the cytotoxic activity against the growth of cells in culture.</p><p id="P21" class="p p-last">In summary, nine 2-amino-4-<em>m</em>-bromoanilino-6-benzyl pyrrolo[ 2,3-<em>d</em>]pyrimidines <strong>4</strong>&#x02013;<strong>12</strong> were designed and synthesized as RTK inhibitors. The preliminary evaluation indicates that the compounds have high potency as antiangiogenic agents as indicated in the CAM assay. 4-N-Methylated compounds <strong>7</strong> and <strong>10</strong> showed the best activities and were better than the lead analogues. Compound <strong>10</strong> exhibited ninefold improved potency over sunitinib against PDGFR-&#x003b2; in the whole cell assay. Thus, mono- and di-methylation affords compounds with increased potency against EGFR and PDGFR-&#x003b2; compared to the corresponding desmethyl compounds. N-Methylation was detrimental to whole cell VEGFR-2 activity. Thus methylation at the 4-N or N7 position can be observed to influence inhibitory activity against the tested kinases. With the exception of <strong>5</strong>, the CAM assay indicates that all the other 4-N-methylated, N7-methylated and 4-N, N7-dimethylated analogues have good antiangiogenic activity comparable to the lead analogues <strong>1</strong>&#x02013;<strong>3</strong> indicating that methylation at either or both positions do not hinder or enhance antiangiogenesis in the CAM assay. However, a clear cut SAR is not possible since these are whole cell assays and cell penetration and transport need to be considered and because multiple growth factors, RTKs and endogenous antiangiogenic molecules contribute to blood vessel growth in the CAM model. Since cell culture inhibitory studies afford the best models for translation to whole animal in vivo models we elected to use whole cell assays. Molecular modeling studies indicate the presence of multiple low energy binding modes for these molecules and explain, in part, the potent activities of <strong>7</strong>, <strong>10</strong>, and <strong>12</strong>. Thus, while general activity trends can be observed, it would be challenging to predict the preferred binding modes for these compounds in receptor tyrosine kinases. Compounds <strong>7</strong> and <strong>10</strong> are projected to start in vivo studies in the near future.</p></div><div id="S4" class="tsec sec"><h2 class="head no_bottom_margin" id="S4title">4. Experimental</h2><p id="P22" class="p p-first">Melting points were determined on a Mel-Temp II melting point apparatus with FLUKE 51 K/J electronic thermometer and are uncorrected. Nuclear magnetic resonance spectra for proton (<sup>1</sup>H) were recorded on a Bruker WH-300 (300 MHz) spectrometer. The chemical shift values are expressed in ppm (parts per million) relative to tetramethylsilane as internal standard; s = singlet, d = double, t = triplet, q = quartet, m = multiplet, br s = broad singlet. The relative integrals of peak areas agreed with those expected for the assigned structures. Thin-layer chromatography (TLC) was performed on Polygram Sil G/UV254 silica gel plates with fluorescent indicator, and the spots were visualized under 254 and 365 nm illumination. Proportions of solvents used for TLC were by volume. Column chromatography was performed on 230&#x02013;400 mesh silica gel purchased from Aldrich Chemical Co., Milwaukee, WI, USA. All evaporations were carried out in vacuo with a rotary evaporator. Analytical samples were dried in vacuo (0.2 mmHg) in an Abderhalden drying apparatus over P<sub>2</sub>O<sub>5</sub> at 75&#x02013;110 &#x000b0;C. Elemental analysis was performed by Atlantic Microlabs, Norcross, GA, USA. Element compositions are within &#x000b1;0.4% of calculated values. Fractional moles of water or organic solvents frequently found in some analytical samples could not be prevented despite 24&#x02013;48 h of drying in vacuo and were confirmed where possible by their presence in the <sup>1</sup>H NMR spectra. All solvents and chemicals were purchased from Aldrich Chemical Co. and Fisher Scientific and were used as received.</p><div id="S5" class="sec"><h3 id="S5title">4.1. General procedure for the synthesis of compounds 15a&#x02013;c</h3><p id="P23" class="p p-first">In a 100 mL flask was placed 50% aqueous KOH solution (12 mL) and ether (40 mL). The mixture was cooled to 0&#x02013;5 &#x000b0;C and nitrosomethylurea (5.9 g, 40 mmol) was added in part, stirring and the temperature maintained below 5 &#x000b0;C, the yellow solution was separated from water and dried with pellets of KOH. The ethereal diazomethane solution was used immediately for next step.</p><p id="P24">A solution of substituted phenyl acetic acid <strong>13a</strong>&#x02013;<strong>c</strong> (5 mmol) in dry benzene (5 mL) and thionyl chloride (5 mL) was heated at reflux for 1 h and the solution was evaporated in vacuo. The resulting acid chloride was dissolved in ether (8 mL) and added dropwise with stirring to ethereal diazomethane at 0&#x02013;5 &#x000b0;C. The yellow solution was allowed to stand at room temperature for 1 h, then hydrobromic acid (5 mL) was added dropwise to the solution and the yellow mixture was heated at 70&#x02013;80 &#x000b0;C (oil bath) for 1 h. The reaction mixture was cooled to room temperature and the ether layer was separated, washed with water (10 mL), saturated NaHCO<sub>3</sub> aqueous solution (10 mL) and water (10 mL) and dried (anhydrous Na<sub>2</sub>SO<sub>4</sub>). The solution was evaporated to afford the &#x003b1;-bromomethyl substituted benzyl ketones <strong>14a</strong>&#x02013;<strong>c</strong>. The compounds were not purified further and were used directly for the next step.</p><p id="P25" class="p">The &#x003b1;-bromomethyl substituted benzyl ketones <strong>14a</strong>&#x02013;<strong>c</strong> were placed in a 50-mL flask and an equivalent amount of 2,6-diamino-pyrimidin-4-one and DMF (15 mL) were added. The mixture was stirred at room temperature for 72 h. To the reaction mixture was added silica gel (3 g) and the solvent was evaporated to afford a plug. The silica gel plug obtained was loaded onto a silica gel column and eluted with CHCl<sub>3</sub>/MeOH (a gradient elution, 2% MeOH in CHCl<sub>3</sub>, and 5% MeOH in CHCl<sub>3</sub>). Fractions containing the product (TLC) were pooled, and the solvent evaporated to afford pure 2-amino-4-oxo-6-substituted benzyl-pyrrolo[2,3-<em>d</em>]pyrimidines <strong>15a</strong>&#x02013;<strong>c</strong>.</p><div id="S6" class="sec"><p></p><h4 id="S6title" class="inline">4.1.1. 2-Amino-4-oxo-6-benzyl-pyrrolo[2,3-<em>d</em>]pyrimidine (15a) </h4><p id="P26" class="p p-first-last">Compound <strong>15a</strong> was synthesized from <strong>13a</strong> (1.5 g, 8.9 mmol) using the general procedure described above and was obtained as a gray white solid (0.78 g, 37% for two steps): <em>R</em><sub>f</sub> 0.5 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 5:1); mp 270 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 3.91 (s, 2H, CH<sub>2</sub>), 5.84 (s, 1H, C5-CH), 6.0 (br s, 2H, NH<sub>2</sub>, exch), 7.10&#x02013;7.30 (m, 5H, Ar-H), 11.10 (br s, 1H, NH, exch), 11.78 (s, 1H, NH, exch).</p></div><div id="S7" class="sec"><p></p><h4 id="S7title" class="inline">4.1.2. 2-Amino-4-oxo-6-(2-methylbenzyl)-pyrolo[2,3-<em>d</em>] pyrimidine (15b) </h4><p id="P27" class="p p-first-last">Compound <strong>15b</strong> was synthesized from <strong>13b</strong> (3.0 g, 20 mmol) using the general procedure described above and was obtained as a light red solid (1.02 g, 20% for two steps): <em>R</em><sub>f</sub> 0.52 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 5:1); mp 290 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 2.22 (s, 3H, CH<sub>3</sub>), 3.79 (s, 2H, CH<sub>2</sub>), 5.68 (s, 1H, C5-CH), 5.99 (br s, 2H, NH<sub>2</sub>, exch), 7.15&#x02013;7.30 (m, 4H, Ar-H), 10.15 (br s, 1H, NH, exch), 10.92 (s, 1H, NH, exch).</p></div><div id="S8" class="sec sec-last"><p></p><h4 id="S8title" class="inline">4.1.3. 2-Amino-4-oxo-6-(2,5-dimethoxybenzyl)-pyrolo[2,3-<em>d</em>] pyrimidine (15c) </h4><p id="P28" class="p p-first-last">Compound <strong>15c</strong> was synthesized from <strong>13c</strong> (3.92 g, 20 mmol) using the general procedure described above and was obtained as a light yellow solid (1.42 g, 24% for two steps): <em>R</em><sub>f</sub> 0.61 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 5:1); mp 275 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 3.65 (s, 3H, CH<sub>3</sub>), 3.73 (s, 3H, CH<sub>3</sub>), 5.77 (s, 1H, C5-CH), 5.99 (br s, 2H, NH<sub>2</sub>, exch), 6.67&#x02013;6.89 (m, 3H, Ar-H), 10.15 (br s, 1H, NH, exch), 11.0 (br s, 1H, NH, exch).</p></div></div><div id="S9" class="sec"><h3 id="S9title">4.2. General procedure for the synthesis of compounds 16a&#x02013;c</h3><p id="P29" class="p p-first">The appropriate compound <strong>15a</strong>&#x02013;<strong>c</strong> and trimethylacetic anhydride was heated at reflux for 3 h. The cooled solution was poured into a large quantity of hexane and the precipitate obtained was filtered and dried over P<sub>2</sub>O<sub>5</sub>. The compounds obtained were used for the next reaction without further purification.</p><div id="S10" class="sec"><p></p><h4 id="S10title" class="inline">4.2.1. 2-Pivaloylamino-4-oxo-6-benzyl-pyrrolo[2,3-<em>d</em>] pyrimidine (16a) </h4><p id="P30" class="p p-first-last">Compound <strong>16a</strong> was synthesized from <strong>15a</strong> (0.33 g, 1.37 mmol) using the general procedure described above and was obtained as a light brown solid (0.32 g, 71%): <em>R</em><sub>f</sub> 0.50 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 230 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 1.23 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 3.95 (s, 2H, CH<sub>2</sub>), 6.05 (s, 1H, C5-CH), 7.23&#x02013;7.30 (m, 5H, Ar-H), 10.75 (br s, 1H, NH, exch), 11.60 (br s, 1H, NH, exch), 11.88 (br s, 1H, NH, exch).</p></div><div id="S11" class="sec"><p></p><h4 id="S11title" class="inline">4.2.2. 2-Pivaloylamino-4-oxo-6-(2-methylbenzyl)-pyrrolo[2,3-<em>d</em>]pyrimidine (16b) </h4><p id="P31" class="p p-first-last">Compound <strong>16b</strong> was synthesized from <strong>15b</strong> (0.58 g, 2.28 mmol) using the general procedure described above and was obtained as a light red solid (0.52 g, 67%): <em>R</em><sub>f</sub> 0.65 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 5:1); mp 260 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 1.24 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 2.27 (s, 3H, CH<sub>3</sub>), 3.93 (s, 2H, CH<sub>2</sub>), 5.88 (s, 1H, C5-CH), 7.07&#x02013;7.17 (m, 4H, Ar-H), 10.76 (br s, 1H, NH, exch), 11.51 (br s, 1H, NH, exch), 11.81 (br s, 1H, NH, exch).</p></div><div id="S12" class="sec sec-last"><p></p><h4 id="S12title" class="inline">4.2.3. 2-Pivaloylamino-4-oxo-6-(2,5-dimethoxybenzyl)-pyrrolo [2,3-<em>d</em>]pyrimidine (16c) </h4><p id="P32" class="p p-first-last">Compound <strong>16c</strong> was synthesized from <strong>15c</strong> (0.53 g, 1.38 mmol) using the general procedure described above and was obtained as a light yellow solid (0.55 g, 81%): <em>R</em><sub>f</sub> 0.45 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 250 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>); <em>&#x003b4;</em> 1.20 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 3.65 (s, 3H, OCH<sub>3</sub>), 3.74 (s, 3H, OCH<sub>3</sub>), 3.86 (s, 2H, CH<sub>2</sub>), 5.96 (s, 1H, C5-CH), 6.60&#x02013;6.93 (m, 3H, Ar-H), 10.75 (br s, 1H, NH, exch), 11.53 (br s, 1H, NH, exch), 11.87 (br s, 1H, NH, exch).</p></div></div><div id="S13" class="sec"><h3 id="S13title">4.3. General procedure for the synthesis of 17a&#x02013;c</h3><p id="P33" class="p p-first">In a 50 mL round-bottom flask was placed <strong>16a</strong>&#x02013;<strong>c</strong> and POCl<sub>3</sub> (5 mL). The mixture was heated to reflux for 2 h. After evaporation of the excess of POCl<sub>3</sub>, ice-cold water was added. The reaction mixture was neutralized with NH<sub>3</sub>&#x000b7;H<sub>2</sub>O, and extracted with CHCl<sub>3</sub> (3&#x000d7;50 mL). The organic phase was combined and dried with Na<sub>2</sub>SO<sub>4</sub>. Concentration of the chloroform afforded a brown solid that was dissolved in chloroform (2&#x02013;3 mL) again and was placed to the top of a 15 &#x000d7; 150 mm chromatographic column and eluted with 0.1% methanol in chloroform. Fractions containing the product were pooled and evaporated to afford pure compounds <strong>17a</strong>&#x02013;<strong>c</strong>.</p><div id="S14" class="sec"><p></p><h4 id="S14title" class="inline">4.3.1. 2-Pivaloylamino-4-chloro-6-benzyl-pyrolo[2,3-<em>d</em>] pyrimidine (17a) </h4><p id="P34" class="p p-first-last">Compound <strong>17a</strong> was synthesized from <strong>16a</strong> (0.30 g, 0.92 mmol) using the general procedure described above and was obtained as a yellow solid (0.10 g, 31%): <em>R</em><sub>f</sub> 0.50 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 131.3&#x02013;133.1 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 1.20 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 4.07 (s, 2H, CH<sub>2</sub>), 6.17 (s, 1H, C5-CH), 7.23&#x02013;7.31 (m, 5H, Ar-H), 9.96 (br s, 1H, NH, exch), 12.36 (br s, 1H, NH, exch).</p></div><div id="S15" class="sec"><p></p><h4 id="S15title" class="inline">4.3.2. 2-Pivaloylamino-4-chloro-6-(2-methylbenzyl)-pyrolo[2,3-<em>d</em>]pyrimidine (17b) </h4><p id="P35" class="p p-first-last">Compound <strong>17b</strong> was synthesized from <strong>16b</strong> (0.50 g, 1.48 mmol) using the general procedure described above and was obtained as a yellow solid (0.20 g, 38%): <em>R</em><sub>f</sub> 0.65 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 80&#x02013;82 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 1.22 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 2.37 (s, 3H, CH<sub>3</sub>), 4.06 (s, 2H, CH<sub>2</sub>), 5.98 (s, 1H, C5-CH), 7.17&#x02013;7.19 (m, 4H, Ar-H), 10.00 (br s, 1H, NH, exch), 12.37 (br s, 1H, NH, exch).</p></div><div id="S16" class="sec sec-last"><p></p><h4 id="S16title" class="inline">4.3.3. 2-Pivaloylamino-4-chloro-6-(2,5-dimethoxybenzyl)-pyrolo[2,3-<em>d</em>]pyrimidine (17c) </h4><p id="P36" class="p p-first-last">Compound <strong>17c</strong> was synthesized from <strong>16c</strong> (0.55 g, 1.43 mmol) using the general procedure described above and was obtained as a yellow solid (0.45 g, 78%): <em>R</em><sub>f</sub> 0.69 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 129.0&#x02013;131.5 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 1.25 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 3.83 (s, 3H, OCH<sub>3</sub>), 3.98 (s, 3H, OCH<sub>3</sub>), 4.12 (s, 2H, CH<sub>2</sub>), 6.02 (s, 1H, C5-CH), 6.78&#x02013;6.94 (m, 3H, Ar-H), 9.96 (br s, 1H, NH, exch), 12.28 (br s, 1H, NH, exch).</p></div></div><div id="S17" class="sec"><h3 id="S17title">4.4. General procedure for the synthesis of compounds4, 7, and 10</h3><p id="P37" class="p p-first">Compounds <strong>17a</strong>&#x02013;<strong>c</strong> and 3-bromo-<em>N</em>-methyl aniline (1.5 equiv), <em>i</em>-PrOH (10 mL), and 2&#x02013;3 drops of conc HCl were placed in a 50-mL flask. The mixture was heated to reflux overnight. After evaporation of the solvent, the residue was dissolved in 1,4-dioxane (10 mL), and 15% KOH aqueous solution (2 mL) was added. The reaction mixture was heated to reflux for 10 h. The solvent was removed under reduced pressure to give syrup. Water (20 mL) was added and the solution was extracted with chloroform (3&#x000d7;50 mL). The organic phase was combined and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the chloroform afforded a solid that was dissolved in methanol, and then 250 mg silica gel was added and the solvent removed in vacuo to afford a dry plug. This plug was placed on the top of a 15 &#x000d7; 150 mm column and eluted with chloroform. Fractions containing the product (tlc) were pooled and evaporated to afford pure <strong>4</strong>, <strong>7</strong>, and <strong>10</strong>.</p><div id="S18" class="sec"><p></p><h4 id="S18title" class="inline">4.4.1. 2-Amino-4-(<em>N</em>-methyl-<em>m</em>-bromoanilino)-6-benzyl-pyrrolo [2,3-<em>d</em>]pyrimidine (4) </h4><p id="P38" class="p p-first-last">Compound <strong>4</strong> was synthesized from <strong>17a</strong> (0.20 g, 0.58 mmol) using the general procedure described above and was obtained as a light yellow solid (33 mg, 14%): <em>R</em><sub>f</sub> 0.33 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 179.5&#x02013;180.7 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 3.42 (s, 3H, NCH<sub>3</sub>), 3.68 (s, 2H, CH<sub>2</sub>), 4.34 (s, 1H, CH), 5.63 (br s, 2H, NH<sub>2</sub>, exch), 7.1&#x02013;7.4 (m, 5H, Ar-H), 10.77 (br s, 1H, NH, exch). Anal. (C<sub>20</sub>H<sub>18</sub>BrN<sub>5</sub>): C, H, N, Br.</p></div><div id="S19" class="sec"><p></p><h4 id="S19title" class="inline">4.4.2. 2-Amino-4-(<em>N</em>-methyl-<em>m</em>-bromoanilino)-6-(2-methyl benzyl)-pyrrolo[2,3-<em>d</em>]pyrimidine (7) </h4><p id="P39" class="p p-first-last">Compound <strong>7</strong> was synthesized from <strong>17b</strong> (0.20 g, 0.58 mmol) using the general procedure described above and was obtained as a white-off solid (25 mg, 14%): <em>R</em><sub>f</sub> 0.51 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 176.6&#x02013;177.9 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 2.27 (s, 3H, CH<sub>3</sub>-Ph), 3.66 (s, 3H, NCH<sub>3</sub>), 4.12 (s, 2H, CH<sub>2</sub>), 5.72 (br s, 2H, NH<sub>2</sub>, exch), 6.99 (s, 1H, C5-CH), 7.07&#x02013;7.41 (m, 7H, Ar-H), 10.79 (br s, 1H, NH, exch). Anal. (C<sub>21</sub>H<sub>20</sub>BrN<sub>5</sub>): C, H, N, Br.</p></div><div id="S20" class="sec sec-last"><p></p><h4 id="S20title" class="inline">4.4.3. 2-Amino-4-(<em>N</em>-methyl-<em>m</em>-bromoanilino)-6-(2,5-dimethoxybenzyl)-pyrrolo[2,3-<em>d</em>]pyrimidine (10) </h4><p id="P40" class="p p-first-last">Compound <strong>10</strong> was synthesized from <strong>17c</strong> (0.15 g, 0.42 mmol) using the general procedure described above and was obtained as a white-off solid (35 mg, 20%): <em>R</em><sub>f</sub> 0.52 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 212&#x02013;214 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 3.39 (s, 3H, NCH<sub>3</sub>), 3.57 (s, 3H, OCH<sub>3</sub>), 3.63 (s, 3H, OCH<sub>3</sub>), 4.24 (s, 2H, CH<sub>2</sub>), 5.62 (br s, 2H, NH<sub>2</sub>, exch), 6.6 (s, 1H, C5-CH), 6.82&#x02013;6.69 (m, 3H, Ar-H), 7.26&#x02013;7.43 (m, 3H, Ar-H), 10.7 (br s, 1H, NH, exch). Anal. (C<sub>22</sub>H<sub>22</sub>BrN<sub>5</sub>O<sub>2</sub>&#x000b7;0.9CH<sub>3</sub>OH): C, H, N, Br.</p></div></div><div id="S21" class="sec"><h3 id="S21title">4.5. General procedure for the synthesis of 18a&#x02013;c</h3><p id="P41" class="p p-first">Compounds <strong>17a</strong>&#x02013;<strong>c</strong> were dissolved in THF (10 mL) and cooled down to 0 &#x000b0;C, 1.5 equiv NaH was added into the mixture and stirred for 10 min. adding the MeI dropwise to the reaction mixture and stirring for another 3 h. Water (10 mL) was added slowly to the reaction solution in an ice-bath, and the solution was extracted with ethyl acetate (3 &#x000d7; 50 mL). The organic phase was combined and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. Concentration of the ethyl acetate afforded a solid that was dissolved in methanol, and then 250 mg silica gel was added and removed the solvent in vacuo to afford a dry plug. This plug was placed on the top of a 15 &#x000d7; 150 mm column and eluted with chloroform. Fractions containing the product were pooled and evaporated to afford <strong>18a</strong>&#x02013;<strong>c</strong>.</p><div id="S22" class="sec"><p></p><h4 id="S22title" class="inline">4.5.1. 2-Pivaloylamino-4-chloro-6-benzyl-7-methyl-pyrrolo [2,3-<em>d</em>]pyrimidine (18a) </h4><p id="P42" class="p p-first-last">Compound <strong>18a</strong> was synthesized from <strong>17a</strong> (0.15 g, 0.42 mmol) using the general procedure described above and was obtained as a white-off solid (90 mg, 58%): <em>R</em><sub>f</sub> 0.84 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 190.5&#x02013;192.1 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 1.21 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 3.60 (s, 3H, NCH<sub>3</sub>), 4.22 (s, 2H, CH<sub>2</sub>), 6.18 (s, 1H, C5-CH), 7.28&#x02013;7.35 (m, 5H, Ar-H), 10.04 (br s, 1H, NH, exch).</p></div><div id="S23" class="sec"><p></p><h4 id="S23title" class="inline">4.5.2. 2-Pivaloylamino-4-chloro-6-(2-methylbenzyl)-7-methylpyrrolo[ 2,3-<em>d</em>]pyrimidine (18b) </h4><p id="P43" class="p p-first-last">Compound <strong>18b</strong> was synthesized from <strong>17b</strong> (0.35 g, 0.98 mmol) using the general procedure described above and was obtained as a yellow solid (0.2 g, 56%): <em>R</em><sub>f</sub> 0.86 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 180.9&#x02013;182.2 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 1.23 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 2.37 (s, 3H, CH<sub>3</sub>), 3.67 (s, 3H, NCH<sub>3</sub>), 4.16 (s, 2H, CH<sub>2</sub>), 5.98 (s, 1H, C5-CH), 7.17&#x02013;7.19 (m, 4H, Ar-H), 10.09 (br s, 1H, NH, exch).</p></div><div id="S24" class="sec sec-last"><p></p><h4 id="S24title" class="inline">4.5.3. 2-Pivaloylamino-4-chloro-6-(2,5-dimethoxybenzyl)-7-methyl-pyrrolo[2,3-<em>d</em>]pyrimidine (18c) </h4><p id="P44" class="p p-first-last">Compound <strong>18c</strong> was synthesized from <strong>17c</strong> (0.45 g, 1.11 mmol) using the general procedure described above and was obtained as a yellow solid (0.36 g, 77%): <em>R</em><sub>f</sub> 0.84 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 77.3&#x02013;78.7 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 1.23 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 3.26 (s, 3H, NCH<sub>3</sub>), 3.66 (s, 3H, OCH<sub>3</sub>), 3.85 (s, 3H, OCH<sub>3</sub>), 4.18 (s, 2H, CH<sub>2</sub>), 6.12 (s, 1H, C5-CH), 6.63&#x02013;7.0 (m, 3H, Ar-H), 10.13 (br s, 1H, NH, exch).</p></div></div><div id="S25" class="sec"><h3 id="S25title">4.6. General procedure for the synthesis of 5, 8, and 11</h3><p id="P45" class="p p-first">Compounds <strong>18a</strong>&#x02013;<strong>c</strong> and 3-bromo-aniline (1.5 equiv), <em>i</em>-PrOH (10 mL), and 2&#x02013;3 drops of conc. HCl were placed in a 50-mL flask. The mixture was heated to reflux for 45 m. After evaporation of the solvent, the residue was dissolved in 1,4-dioxane (10 mL), and 15% KOH aqueous solution (2 mL) was added. The reaction mixture was heated to reflux for 10 h. The solvent was removed under reduced pressure to give syrup, and then water (20 mL) was added and the solution was extracted with chloroform (3 &#x000d7; 50 mL). The organic phase was combined and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. Concentration of the chloroform afforded a residue that was dissolved in methanol, and then 250 mg silica gel was added and removed the solvent in vacuo to afford a dry plug. This plug was placed on the top of a 15 &#x000d7; 150 mm column and eluted with 2% methanol in chloroform. Fractions containing the product were pooled and evaporated to afford pure <strong>5</strong>, <strong>8</strong>, and <strong>11</strong>.</p><div id="S26" class="sec"><p></p><h4 id="S26title" class="inline">4.6.1. 2-Amino-4-(<em>m</em>-bromoanilino)-6-benzyl-7-methyl-pyrrolo-[2,3-<em>d</em>]pyrimidine (5) </h4><p id="P46" class="p p-first-last">Compound <strong>5</strong> was synthesized from <strong>18a</strong> (0.10 g, 0.28 mmol) using the general procedure described above and was obtained as a yellow solid (63 mg, 55%): <em>R</em><sub>f</sub> 0.53 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 155.7&#x02013;157.6 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 3.66 (s, 3H, NCH<sub>3</sub>), 4.03 (s, 2H, CH<sub>2</sub>), 5.89 (br s, 2H, NH<sub>2</sub>, exch), 6.18 (s, 1H, C5-CH), 7.06&#x02013;7.35 (m, 5H, Ar-H), 8.01&#x02013;8.11 (m, 2H, Ar-H), 8.98 (br s, 1H, NH, exch). Anal. (C<sub>20</sub>H<sub>18</sub>BrN<sub>5</sub>): C, H, N, Br.</p></div><div id="S27" class="sec"><p></p><h4 id="S27title" class="inline">4.6.2. 2-Amino-4-(<em>m</em>-bromoanilino)-6-(2-methylbenzyl)-7-methyl-pyrrolo[2,3-<em>d</em>]pyrimidine (8) </h4><p id="P47" class="p p-first-last">Compound <strong>8</strong> was synthesized from <strong>18b</strong> (0.13 g, 0.35 mmol) using the general procedure described above and was obtained as a yellow solid (86 mg, 58%): <em>R</em><sub>f</sub> 0.26 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 20:1); mp 173.5&#x02013;174.1 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 2.36 (s, 3H, CH<sub>3</sub>-Ph), 3.6 (s, 3H, CH<sub>3</sub>N), 3.9 (s, 2H, CH<sub>2</sub>), 5.92 (br s, 2H, NH<sub>2</sub>, exch), 5.98 (s, 1H, CH), 7.06&#x02013;7.21 (m, 4H, Ph-H), 8.01&#x02013;8.08 (m, 3H, Ph-H), 9.0 (br s, 1H, NH, exch). Anal. (C<sub>21</sub>H<sub>20</sub>BrN<sub>5</sub>): C, H, N, Br.</p></div><div id="S28" class="sec sec-last"><p></p><h4 id="S28title" class="inline">4.6.3. 2-Amino-4-(<em>m</em>-bromoanilino)-6-(2,5-dimethoxybenzyl)-7-methyl-pyrrolo[2,3-<em>d</em>]pyrimidine (11) </h4><p id="P48" class="p p-first-last">Compound <strong>11</strong> was synthesized from <strong>18c</strong> (0.20 g, 0.48 mmol) using the general procedure described above and was obtained as a yellow solid (95 mg, 42%): <em>R</em><sub>f</sub> 0.41 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 5:1); mp 78&#x02013;80 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 3.45 (s, 3H, NCH<sub>3</sub>), 3.69 (s, 3H, OCH<sub>3</sub>), 3.73 (s, 3H, OCH<sub>3</sub>), 3.91 (s, 2H, CH<sub>2</sub>), 5.84 (br s, 2H, NH<sub>2</sub>, exch), 6.09 (s, 1H, C5-CH), 6.66&#x02013;7.18 (m, 5H, Ar-H), 8.00&#x02013;8.10 (m, 2H, Ar-H), 8.93 (br s, 1H, NH, exch). Anal. (C<sub>22</sub>H<sub>22</sub>BrN<sub>5</sub>O<sub>2</sub>&#x000b7;0.6-CH<sub>3</sub>OH): C, H, N, Br.</p></div></div><div id="S29" class="sec sec-last"><h3 id="S29title">4.7. General procedure for the synthesis of 6, 9, and 12</h3><p id="P49" class="p p-first">Compound <strong>18a&#x02013;c</strong>, 3-bromo-<em>N</em>-methyl aniline (1.5 equiv), <em>i</em>-PrOH (10 mL), and 2&#x02013;3 drops of conc. HCl were placed in a 50-mL flask. The mixture was heated to reflux for 45 m. After evaporation of the solvent, the residue was dissolved in 1,4-dioxane (10 mL), and 15% KOH aqueous solution (2 mL) was added. The reaction mixture was heated to reflux for 10 h. The solvent was removed under reduced pressure, and then water (20 mL) was added and the resulted solution was extracted with chloroform (3 &#x000d7; 50 mL). The organic phase was combined and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. Concentration of the chloroform-afforded a solid that was dissolved in methanol, and then 250 mg silica gel was added and removed the solvent in vacuo to afford a dry plug. This plug was placed on the top of a 15 &#x000d7; 150 mm column and eluted with 2% methanol in chloroform. Fractions containing the product were pooled and evaporated to afford pure <strong>6</strong>, <strong>8</strong>, and <strong>12</strong>.</p><div id="S30" class="sec"><p></p><h4 id="S30title" class="inline">4.7.1. 2-Amino-4-(<em>N</em>-methyl-<em>m</em>-bromoanilino)-6-benzyl-7-methyl-pyrrolo[2,3-<em>d</em>]pyrimidine (6) </h4><p id="P50" class="p p-first-last">Compound<strong>6</strong> was synthesized from <strong>18a</strong> (0.17 g, 0.48 mmol)using the general procedure described above and was obtained as a yellow solid (55 mg, 27%): <em>R</em><sub>f</sub> 0.52 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 187.1&#x02013;190.4 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 3.42 (s, 3H, NCH<sub>3</sub>), 3.80 (s, 3H, NCH<sub>3</sub>), 4.30 (s, 2H, CH<sub>2</sub>), 5.79 (br s, 2H, NH<sub>2</sub>, exch), 6.99 (s, 1H, CH), 7.04&#x02013;7.42 (m, 8H, Ar-H). Anal. (C<sub>21</sub>H<sub>20</sub>BrN<sub>5</sub>&#x000b7;0.2H<sub>2</sub>O): C, H, N, Br.</p></div><div id="S31" class="sec"><p></p><h4 id="S31title" class="inline">4.7.2. 2-Amino-4-(<em>N</em>-methyl-<em>m</em>-bromoanilino)-6-(2-methylbenzyl)-7-methyl-pyrrolo[2,3-<em>d</em>]pyrimidine (9) </h4><p id="P51" class="p p-first-last">Compound <strong>9</strong> was synthesized from <strong>18b</strong> (0.20 g, 0.54 mmol) using the general procedure described above and was obtained as a white-off solid (78 mg, 33%): <em>R</em><sub>f</sub> 0.40 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 184&#x02013;186.5 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 2.15 (s, 3H, CH<sub>3</sub>), 3.38 (s, 3H, NCH<sub>3</sub>), 3.40 (s, 3H, NCH<sub>3</sub>), 3.76 (s, 2H, CH<sub>2</sub>), 4.08 (s, 1H, CH), 5.78 (br s, 2H, NH<sub>2</sub>, exch), 6.82&#x02013;7.38 (m, 8H, Ph-H). Anal. (C<sub>22</sub>H<sub>22</sub>BrN<sub>5</sub>&#x000b7;0.2H<sub>2</sub>O): C, H, N, Br.</p></div><div id="S32" class="sec sec-last"><p></p><h4 id="S32title" class="inline">4.7.3. 2-Amino-4-(<em>N</em>-methyl-<em>m</em>-bromoanilino)-6-(2,5-dimethoxybenzyl)-7-methyl-pyrrolo[2,3-<em>d</em>]pyrimidine (12) </h4><p id="P52" class="p p-first-last">Compound <strong>12</strong> was synthesized from <strong>18c</strong> (0.09 g, 0.22 mmol) using the general procedure described above and was obtained as a white-off solid (27 mg, 25%): <em>R</em><sub>f</sub> 0.53 (CHCl<sub>3</sub>/CH<sub>3</sub>OH, 10:1); mp 153.6&#x02013;154.3 &#x000b0;C; <sup>1</sup>H NMR (DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 3.48 (s, 3H, NCH<sub>3</sub>, 3.63 (s, 3H, OCH<sub>3</sub>), 3.67 (s, 3H, OCH<sub>3</sub>), 4.2 (s, 2H, CH<sub>2</sub>), 5.79 (br s, 2H, NH<sub>2</sub>, exch), 6.41 (s, 1H, CH), 6.75&#x02013;6.78 (m, 3H, Ph-H), 7.26&#x02013;7.43 (m, 3H, Ph-H). Anal. (C<sub>23</sub>H<sub>24</sub>BrN<sub>5</sub>O<sub>2</sub>&#x000b7;0.7CH<sub>3</sub>OH): C, H, N, Br.</p></div></div></div><div id="S33" class="tsec sec"><h2 class="head no_bottom_margin" id="S33title">5. Molecular modeling</h2><p id="P53" class="p p-first">Molecular modeling was performed using the X-ray crystal structure of erlotinib bound to EGFR (PDB ID: 1M17) using Flexx 3.1.2. The active site for docking was defined using amino acids within 6.5 &#x000c5; cocrystallized ligand in the crystal structure. Polar hydrogen atoms of Thr766, Cys773, and Thr830 were permitted to rotate freely. Ligands for docking were prepared using the molecule builder in MOE 2009.10. Prior to docking, the ligands were imported into Flexx, atom types, protonation states and formal charges were assigned using default settings. Docking into the active site was performed using Triangle matching. The maximum number of solutions per iteration and the maximum number of solutions per fragment was set at 500. The top 10 poses were retained for each molecule from every docking run. The docked poses were exported and visualized using MOE 2009.10. Ligand interaction plots were calculated using MOE 2009.10.</p><p id="P54">Prior to docking of <strong>1</strong>&#x02013;<strong>12</strong>, a docking run was performed using the native X-ray crystal structure ligand (erlotinib) as described above. The RMSD of the docked conformation of erlotinib was 0.9 &#x000c5; compared to the crystal structure conformation of erlotinib. Flexx 3.1.2 was thus validated for our docking studies.</p><p id="P55" class="p p-last">There is no known X-ray crystal structure of PDGFR-&#x003b2;. Thus, a homology model of PDGFR-&#x003b2; was created<sup><a href="#R25" rid="R25" class=" bibr popnode">25</a></sup> and utilized for docking <strong>1</strong>&#x02013;<strong>12</strong>. Docking studies were performed using Flexx 3.1.2 using the same settings as described above. Docked poses were exported and visualized in MOE 2009.10. Ligand interaction plots were calculated using MOE 2009.10.</p></div><div id="S34" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="S34title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>01</h4><div class="sup-box half_rhythm" id="N0xde9a5c0N0xee96220"><a href="/pmc/articles/PMC2910361/bin/NIHMS210323-supplement-01.doc" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(66K, doc)</sup></div></div></div><div id="S36" class="tsec sec"><h2 class="head no_bottom_margin" id="S36title">Acknowledgments</h2><div class="sec"><p>This work was supported, in part, by the National Institutes of Health and National Cancer Institute Grant CA98850 (A.G.).</p></div></div><div id="GL" class="tsec sec"><h2 class="head no_bottom_margin" id="GLtitle">Abbreviations</h2><div class="bk-sec"><div class="def-list"><dl class="labeled-list"><dt id="G1">RTKs</dt><dd>receptor tyrosine kinases</dd><dt id="G2">PDGFR</dt><dd>platelet-derived growth factor receptor</dd><dt id="G3">FGFR</dt><dd>fibroblast growth factor receptor</dd><dt id="G4">IGFR</dt><dd>insulin growth factor receptor</dd><dt id="G5">VEGFR</dt><dd>vascular endothelial growth factor receptor</dd><dt id="G6">EGFR</dt><dd>epidermal growth factor receptor</dd><dt id="G7">CAM</dt><dd>chicken embryo chorioallantoic membrane</dd></dl></div></div></div><div id="fn-group-a.w.e" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.w.etitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN2"><p class="p p-first"><a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary data</a></p><p class="p p-last"><a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary data</a> (results from elemental analysis. This material is available free of charge via the Internet) associated with this article can be found, in the online version, at doi: 10.1016/j.bmc.2010.05.049.</p></p></div></div><div id="ref-list-a.w.d" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.w.dtitle">References and notes</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="citation">Gangjee A, Zhao Y, Ihnat MA, Green D, Miller WT. The 96th American Association for Cancer Research (AACR) Annual Meeting; Anaheim, CA. April 16&#x02013;20, 2005;  poster number 3946. <span class="nowrap">[<a href="https://scholar.google.com/scholar?q=Gangjee+A+Zhao+Y+Ihnat+MA+Green+D+Miller+WT+The+96th+American+Association+for+Cancer+Research+(AACR)+Annual+Meeting+Anaheim,+CA+April+16&#x02013;20,+2005+poster+number+3946+" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="citation">Folkman J. <span><span class="ref-journal">Nat Rev Drug Disc. </span>2007;<span class="ref-vol">6</span>:273.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17396134" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Drug+Disc&amp;author=J+Folkman&amp;volume=6&amp;publication_year=2007&amp;pages=273&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="citation">Folkman J. <span><span class="ref-journal">Breast Cancer Res Treat. </span>1995;<span class="ref-vol">36</span>:109.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8534860" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;author=J+Folkman&amp;volume=36&amp;publication_year=1995&amp;pages=109&amp;pmid=8534860&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="citation">Bohle AS, Kalthoff H. <span><span class="ref-journal">Langenbecks Arch Surg. </span>1999;<span class="ref-vol">38</span>:4133.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Langenbecks+Arch+Surg&amp;author=AS+Bohle&amp;author=H+Kalthoff&amp;volume=38&amp;publication_year=1999&amp;pages=4133&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="citation">Hanahan D, Folkman J. <span><span class="ref-journal">Cell. </span>1996;<span class="ref-vol">1996</span>:353.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8756718" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;author=D+Hanahan&amp;author=J+Folkman&amp;volume=1996&amp;publication_year=1996&amp;pages=353&amp;pmid=8756718&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="citation">Ellis LM. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>2004;<span class="ref-vol">18</span>:1007, viii.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15474332" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hematol+Oncol+Clin+North+Am&amp;author=LM+Ellis&amp;volume=18&amp;publication_year=2004&amp;pages=1007&amp;pmid=15474332&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="citation">Sun L, McMahon G. <span><span class="ref-journal">Drug Discovery Today. </span>2000;<span class="ref-vol">8</span>:344.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10893547" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Discovery+Today&amp;author=L+Sun&amp;author=G+McMahon&amp;volume=8&amp;publication_year=2000&amp;pages=344&amp;pmid=10893547&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="citation">Dancey J, Sausville EA. <span><span class="ref-journal">Nat Rev Drug Disc. </span>2003;<span class="ref-vol">2</span>:296.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12669029" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Drug+Disc&amp;author=J+Dancey&amp;author=EA+Sausville&amp;volume=2&amp;publication_year=2003&amp;pages=296&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="citation">Bilodeau MT, Fraley ME, Hartman GD. <span><span class="ref-journal">Expert Opin Investig Drugs. </span>2002;<span class="ref-vol">11</span>:737.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12036418" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Opin+Investig+Drugs&amp;author=MT+Bilodeau&amp;author=ME+Fraley&amp;author=GD+Hartman&amp;volume=11&amp;publication_year=2002&amp;pages=737&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="citation">Bergsland EK. <span><span class="ref-journal">Am J Health-Syst Pharm. </span>2004;<span class="ref-vol">61</span>:S12.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15552622" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Health-Syst+Pharm&amp;author=EK+Bergsland&amp;volume=61&amp;publication_year=2004&amp;pages=S12&amp;pmid=15552622&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="citation">Mandel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. <span><span class="ref-journal">Clin Cancer Res. </span>2003;<span class="ref-vol">9</span>:327.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12538485" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;author=DB+Mandel&amp;author=AD+Laird&amp;author=X+Xin&amp;author=SG+Louie&amp;author=JG+Christensen&amp;volume=9&amp;publication_year=2003&amp;pages=327&amp;pmid=12538485&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="citation">Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. <span><span class="ref-journal">Cancer Res. </span>2004;<span class="ref-vol">64</span>:7099.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15466206" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;author=SM+Wilhelm&amp;author=C+Carter&amp;author=L+Tang&amp;author=D+Wilkie&amp;author=A+McNabola&amp;volume=64&amp;publication_year=2004&amp;pages=7099&amp;pmid=15466206&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="citation">Furet P, Caravatti G, Lydon N, Priestle J, Sowadski J, Trinks U, Traxler P. <span><span class="ref-journal">J Comput Aided Mol Des. </span>1995;<span class="ref-vol">9</span>:465.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8789188" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Comput+Aided+Mol+Des&amp;author=P+Furet&amp;author=G+Caravatti&amp;author=N+Lydon&amp;author=J+Priestle&amp;author=J+Sowadski&amp;volume=9&amp;publication_year=1995&amp;pages=465&amp;pmid=8789188&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="citation">Traxler P, Green J, Mett H, Sequin U, Furet P. <span><span class="ref-journal">J Med Chem. </span>1999;<span class="ref-vol">42</span>:1018.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10090785" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;author=P+Traxler&amp;author=J+Green&amp;author=H+Mett&amp;author=U+Sequin&amp;author=P+Furet&amp;volume=42&amp;publication_year=1999&amp;pages=1018&amp;pmid=10090785&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="citation">Gangjee A, Yang J, Ihnat M, Kamat S. <span><span class="ref-journal">Bioorg Med Chem. </span>2003;<span class="ref-vol">11</span>:5155.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14604679" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg+Med+Chem&amp;author=A+Gangjee&amp;author=J+Yang&amp;author=M+Ihnat&amp;author=S+Kamat&amp;volume=11&amp;publication_year=2003&amp;pages=5155&amp;pmid=14604679&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="citation">Gangjee A, Kurup S, Ihnat MA, Green D. <span></span> unpublished results. <span class="nowrap">[<a href="https://scholar.google.com/scholar?q=Gangjee+A+Kurup+S+Ihnat+MA+Green+D+unpublished+results+" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="citation">Gangjee A, Namjoshi O, Yu J, Ihnat MA, Thorpe JE, Warnke LA. <span><span class="ref-journal">Bioorg Med Chem. </span>2008;<span class="ref-vol">16</span>:5514.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2474725/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18467105" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg+Med+Chem&amp;author=A+Gangjee&amp;author=O+Namjoshi&amp;author=J+Yu&amp;author=MA+Ihnat&amp;author=JE+Thorpe&amp;volume=16&amp;publication_year=2008&amp;pages=5514&amp;pmid=18467105&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="citation">Stamos J, Sliwkowski MX, Eigenbrot C. <span><span class="ref-journal">J Biol Chem. </span>2002;<span class="ref-vol">277</span>:46265.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12196540" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;author=J+Stamos&amp;author=MX+Sliwkowski&amp;author=C+Eigenbrot&amp;volume=277&amp;publication_year=2002&amp;pages=46265&amp;pmid=12196540&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="citation"><span class="ref-journal">Flexx 3.1.2 BioSolveIT GmbH, An der Ziegelei.</span> Vol. 79. Sankt Augustin Germany; p. 53757.  <a href="http://www.biosolveit.de" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.biosolveit.de</a>. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Flexx+3.1.2+BioSolveIT+GmbH,+An+der+Ziegelei&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="citation">Constantine KL, Mueller L, Metzler WJ, McDonnell PA, Todderud G, Goldfarb V, Fan Y, Newitt JA, Kiefer SE, Gao M, Tortolani D, Vaccaro W, Tokarski J. <span><span class="ref-journal">J Med Chem. </span>2008;<span class="ref-vol">51</span>:6225.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18771253" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;author=KL+Constantine&amp;author=L+Mueller&amp;author=WJ+Metzler&amp;author=PA+McDonnell&amp;author=G+Todderud&amp;volume=51&amp;publication_year=2008&amp;pages=6225&amp;pmid=18771253&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="citation">Boschelli DH. <span><span class="ref-journal">Curr Top Med Chem. </span>2002;<span class="ref-vol">2</span>:1051.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12171571" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Top+Med+Chem&amp;author=DH+Boschelli&amp;volume=2&amp;publication_year=2002&amp;pages=1051&amp;pmid=12171571&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="citation">Miki A, Miki K, Ueno S, Wersinger DM, Berlinicke C, Shaw GC, Usui S, Wang Y, Zack DJ, Campochiaro PA. <span><span class="ref-journal">J Cell Physiol. </span>2010;<span class="ref-vol">224</span>:262.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4005719/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20232317" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Cell+Physiol&amp;author=A+Miki&amp;author=K+Miki&amp;author=S+Ueno&amp;author=DM+Wersinger&amp;author=C+Berlinicke&amp;volume=224&amp;publication_year=2010&amp;pages=262&amp;pmid=20232317&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="citation">Mol CD, Lim KB, Sridhar V, Zou H, Chien EYT, Sang BC, Nowakowski J, Kassel DB, Cronin CN, McRee DE. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:31461.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12824176" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;author=CD+Mol&amp;author=KB+Lim&amp;author=V+Sridhar&amp;author=H+Zou&amp;author=EYT+Chien&amp;volume=278&amp;publication_year=2003&amp;pages=31461&amp;pmid=12824176&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="citation">MOE (Molecular Operating Environment) Distributor: Chemical Computing Group; 1010 Sherbrooke St. West, #910, Montreal, Canada H3A:   <a href="http://www.chemcomp.com" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.chemcomp.com</a>. <span class="nowrap">[<a href="https://scholar.google.com/scholar?q=MOE+(Molecular+Operating+Environment)+Distributor:+Chemical+Computing+Group+1010+Sherbrooke+St.+West,+#910,+Montreal,+Canada+H3A+http://www.chemcomp.com+" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="citation">Gangjee A, Zaware N, Raghavan S, Ihnat M, Shenoy S, Kisliuk RL. <span><span class="ref-journal">J Med Chem. </span>2010;<span class="ref-vol">53</span>:1563.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2825747/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20092323" ref="reftype=pubmed&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;author=A+Gangjee&amp;author=N+Zaware&amp;author=S+Raghavan&amp;author=M+Ihnat&amp;author=S+Shenoy&amp;volume=53&amp;publication_year=2010&amp;pages=1563&amp;pmid=20092323&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2910361&amp;issue-id=188809&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC2910361/pdf/nihms210323.pdf" class="int-view">PDF (2.4M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/2910361/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/2910361/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="2910361" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2910361%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="ysQsduAtA4otgH41iGQzQf1x66b2wyKRA0aB09lTiyZ2dfOs1laG6qTNdWmxv7FS">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2910361%2F&amp;text=Design%2C%20synthesis%20and%20evaluation%20of%202-amino-4-m-bromoanilino-6-arylmethyl-7%20H-pyrrolo%5B2%2C3-d%5Dpyrimidines%20as%20tyrosine%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2910361%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910361/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC2910361/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/20558072/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC2910361/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/20558072/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC2910361/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/2910361/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC2910361/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
